Antibody-drug conjugates (ADCs) are a newer form of targeted cancer therapy. They help slow the growth of HR-positive/HER2-negative metastatic breast cancer.
Like traditional chemotherapy, ADCs are administered intravenously at an infusion center.
ADCs have two key components that make them highly targeted and potent: 1. Monoclonal antibodies, which target the cancer cells 2. Cytotoxic drugs (chemotherapy), which kill cancer cells
Because the monoclonal antibodies in ADCs bring chemotherapy directly to the cancer cells, damage to healthy cells is reduced.
The side effects of ADCs can be similar to traditional chemotherapy, including fatigue, nausea, and vomiting, but these side effects may be less intense, because the drug is so targeted.
ADCs may slow cancer progression and help people with HR-positive/ HER2-negative metastatic breast cancer live longer.
Replay
